Clinical Trials
14 trialsNCT05210374 2026-06-05
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT07197554 2026-06-02
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Recruiting
NCT03715933 2026-05-22
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
NCT07172958 2026-05-22
SABRE
Children's National Research Institute
Phase 1 Recruiting
NCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT07194044 2026-05-15
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT04337177 2026-05-11
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Active not recruiting
NCT07297979 2026-05-08
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Amgen
Phase 1 Recruiting
NCT04084067 2026-04-30
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04483778 2026-04-28
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT06926283 2026-04-24
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT06566092 2026-04-06
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics, Inc.
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting